Eli Lilly and Company has announced a $1.2B investment to expand its Carolina facility, enhancing its capacity to produce oral drugs, including the highly anticipated GLP-1 treatment, orforglipron
Phaze's Body Composition (Beta) gives you an AI photo estimate of body fat % and muscle, with a confidence level and a 35% margin, plus DEXA scan import
Within this framework, glucagon-like peptide-1 (GLP-1) receptor agonists (RAs), originally developed for the treatment of type 2 diabetes (T2D), have recently shown cardioprotective effects beyond their role in glycaemic control
By wrapping the glutathione molecule in this protective phospholipid bilayer (a double layer of fatty acids), we can shield it from the digestive process
26. Franca RA, Di Crescenzo RM, Ugga L, Della Monica R & DAvella E